Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6548631B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 16, 1997 |
| Grant date | Apr 15, 2003 |
| Priority date | — |
| Expiry date | Sep 16, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to therapeutic compositions of macrophage derived chemokine (MDC) and methods for treating and preventing infection by a lentivirus, particularly an immunodeficiency virus, particularly HIV, using MDC proteins, nucleic acids and/or derivatives or analogues thereof. The present invention further relates to methods for detection and prognosis of lenivirus infection, particularly HIV infection using MDC as a prognostic indicator. The present invention further provides MDC proteins, nucleic acids encoding such proteins, that have amino-terminal sequences that differ from other MDC isolates. Recombinant host cells and methods of production are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.